<DOC>
	<DOCNO>NCT00309920</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Colony-stimulating factor , darbepoetin alfa , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Giving combination chemotherapy together darbepoetin alfa surgery may kill tumor cell remain surgery . It yet know whether combination chemotherapy darbepoetin alfa effective combination chemotherapy alone treat stage III breast cancer . PURPOSE : This randomized clinical trial study well give combination chemotherapy together darbepoetin alfa work compare combination chemotherapy alone treat woman stage III breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Darbepoetin Alfa Treating Women With Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare disease-free survival rate woman stage III breast cancer treat adjuvant chemotherapy v without darbepoetin alfa . Secondary - Compare local recurrence overall survival patient receive regimen . - Compare toxicity regimens patient . - Compare quality life fatigue frequency patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord chemotherapy regimen ( CEF v TAC ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive 1 follow regimen : - Regimen CEF : Patients receive cyclophosphamide IV , epirubicin hydrochloride IV , fluorouracil IV day 1 . - Regimen TAC : Patients receive docetaxel IV , doxorubicin hydrochloride IV , cyclophosphamide IV day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive 1 follow regimen : - Regimen CEF : Patients receive regimen CEF arm I . Patients receive darbepoetin alfa hemoglobin fall ≤ 13.0 g/dL . Darbepoetin alfa discontinue hemoglobin rise &gt; 14.0 g/dL . - Regimen TAC : Patients receive TAC arm I darbepoetin alfa arm II , regimen CEF . Quality life assess baseline , chemotherapy course , completion study therapy , 6 12 month . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 1,234 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Stage III disease ( pT1 , N23 , M0 ) No metastatic disease thoracic xray , fullbody bone scan , liver sonography No inflammatory disease Paget 's disease Disease completely resect ( R0 ) ≥ 10 axillary lymph node remove Underwent surgery approximately 42 day ago At least 9 positive lymph nod No prior sequential mastectomy Hormone receptor status specify PATIENT CHARACTERISTICS : Female Menopausal status specify ECOG performance status 01 WBC ≥ 3,500/mm^3 Creatinine ≤ 1.4 mg/dL Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 2.0 mg/dL No preexisting symptomatic peripheral neuropathy Not pregnant nurse No hypersensitivity darbepoetin alfa , epoetin alfa , components No malignancy except curatively treat basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : See Disease Characteristics No participation another clinical study No prior therapy would preclude study participation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>